These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36252280)

  • 1. The applicability of the Second Revision of the International Staging System for patients with multiple myeloma receiving immunomodulatory drugs or proteasome inhibitor-based regimens as induction treatment: A real-world analysis.
    Chen H; Zhou N; Hu X; Wang D; Wei W; Peng R; Chen X; Shi H; Wu L; Yu W; Zhao W; Zhou F
    Hematol Oncol; 2023 Feb; 41(1):139-146. PubMed ID: 36252280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Application of the Second Revision of the International Staging System (R2-ISS) in the prognostic assessment of newly diagnosed multiple myeloma].
    Yan J; Zhou DM; Shao XY; Xu Y; Chen B
    Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):170-177. PubMed ID: 38604794
    [No Abstract]   [Full Text] [Related]  

  • 3. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project.
    D'Agostino M; Cairns DA; Lahuerta JJ; Wester R; Bertsch U; Waage A; Zamagni E; Mateos MV; Dall'Olio D; van de Donk NWCJ; Jackson G; Rocchi S; Salwender H; Bladé Creixenti J; van der Holt B; Castellani G; Bonello F; Capra A; Mai EK; Dürig J; Gay F; Zweegman S; Cavo M; Kaiser MF; Goldschmidt H; Hernández Rivas JM; Larocca A; Cook G; San-Miguel JF; Boccadoro M; Sonneveld P
    J Clin Oncol; 2022 Oct; 40(29):3406-3418. PubMed ID: 35605179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prognostic value of the Second Revision of the International Staging System in patients with newly diagnosed transplant-eligible multiple myeloma].
    Zhou HX; Jian Y; Du J; Liu JR; Zhang ZY; Geng CY; Yang GZ; Wang GR; Fu WJ; Li J; Chen WM; Gao W
    Zhonghua Nei Ke Za Zhi; 2024 Jan; 63(1):81-88. PubMed ID: 38186122
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation.
    Alzahrani K; Pasvolsky O; Wang Z; Milton DR; Tanner MR; Bashir Q; Srour S; Saini N; Lin P; Ramdial J; Nieto Y; Lee HC; Patel KK; Manasanch EE; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin R; Qazilbash MH
    Br J Haematol; 2024 May; 204(5):1944-1952. PubMed ID: 38448009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of prognostic staging systems of multiple myeloma in the era of novel agents.
    Shang Y; Jin Y; Liu H; Ding L; Tong X; Tu H; Zang L; Lin C; Hu J; Zhou F
    Hematol Oncol; 2022 Apr; 40(2):212-222. PubMed ID: 34860428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of the "dynamic" R2-ISS in patients with multiple myeloma undergoing anti-CD38 antibody-based triplet therapies.
    Kikuchi T; Oda Y; Kondo U; Tsukada N; Kunisada K; Matsumoto C; Nomura-Yogo M; Sato K; Takei T; Ogura M; Abe Y; Suzuki K; Hosoya O; Ishida T
    Hematol Oncol; 2024 Sep; 42(5):e3302. PubMed ID: 39096249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical relevance of high-risk cytogenetic abnormalities and the second revision of the International Staging System (R2-ISS) in patients with multiple myeloma in clinical practice.
    Mizuguchi M; Okamoto Y; Yagi H; Kagawa K; Sekimoto E; Shibata H; Shigekiyo T; Ozaki S
    Int J Hematol; 2023 May; 117(5):718-728. PubMed ID: 36692689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. R2-ISS staging combined with circulating plasma cells improves risk stratification for newly diagnosed multiple myeloma: a single-center real-world study.
    Chu B; Wang YT; Gao S; Shi L; Lu MQ; Fang LJ; Xiang QQ; Chen Y; Wang MZ; Wang LF; Sun K; Yang J; Duan F; Bao L
    Ann Hematol; 2024 Sep; 103(9):3677-3690. PubMed ID: 38955826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS.
    Guo W; Zhan A; Mery DE; Munshi MN; Makhoul O; Baily C; Zangari M; Tricot G; Peng H; Shaughnessy JD
    Blood Adv; 2023 Nov; 7(21):6676-6684. PubMed ID: 37756524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients.
    González-Calle V; Slack A; Keane N; Luft S; Pearce KE; Ketterling RP; Jain T; Chirackal S; Reeder C; Mikhael J; Noel P; Mayo A; Adams RH; Ahmann G; Braggio E; Stewart AK; Bergsagel PL; Van Wier SA; Fonseca R
    Ann Hematol; 2018 Aug; 97(8):1453-1462. PubMed ID: 29623394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Validation of the prognostic value of the Mayo MASS and R2-ISS staging systems in patients newly diagnosed with multiple myeloma: A single-center study].
    Xu Y; Shen XX; Jin YY; Li JY; Chen LJ; Zhang R
    Zhonghua Xue Ye Xue Za Zhi; 2023 Sep; 44(9):749-754. PubMed ID: 38049319
    [No Abstract]   [Full Text] [Related]  

  • 13. The Revised International Staging System Compared to the Classical International Staging System Better Discriminates Risk Groups among Transplant-Ineligible Multiple Myeloma Patients.
    Bila J; Jelicic J; Dencic Fekete M; Trajkovic G; Sretenovic A; Perunicic Jovanovic M; Antic D; Mihaljevic B
    Oncol Res Treat; 2017; 40(10):616-620. PubMed ID: 28950269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic Value of A New Risk Stratification Model (R2-ISS) in Newly Diagnosed Multiple Myeloma].
    Wang Y; Yue LL; Zeng PY; Wu CY; Han Y; Song Y; Jin QQ; Jiang HY; Chai Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1779-1784. PubMed ID: 36476903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The detection of circulating plasma cells may improve the Revised International Staging System (R-ISS) risk stratification of patients with newly diagnosed multiple myeloma.
    Galieni P; Travaglini F; Vagnoni D; Ruggieri M; Caraffa P; Bigazzi C; Falcioni S; Picardi P; Mazzotta S; Troiani E; Dalsass A; Mestichelli F; Angelini M; Camaioni E; Maravalle D; Angelini S; Pezzoni V
    Br J Haematol; 2021 May; 193(3):542-550. PubMed ID: 33792026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].
    Deng SH; Xu Y; Mai YJ; Wang YF; Zhao YZ; Zou DH; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):217-21. PubMed ID: 18843972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma.
    Ozaki S; Handa H; Koiso H; Saitoh T; Sunami K; Ishida T; Suzuki K; Narita T; Iida S; Nakamura Y; Suzuki K; Nishimura N; Murakami H; Shimizu K
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):191-203. PubMed ID: 34080068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma.
    Schavgoulidze A; Lauwers-Cances V; Perrot A; Cazaubiel T; Chretien ML; Moreau P; Facon T; Leleu X; Karlin L; Stoppa AM; Decaux O; Belhadj K; Arnulf B; Mohty M; Ariette CM; Fohrer-Sonntag C; Lenain P; Marolleau JP; Tiab M; Araujo C; Orsini-Piocelle F; Jaccard A; Roussel M; Benboubker L; Eveillard JR; Dib M; Divoux M; Attal M; Avet-Loiseau H; Corre J
    Haematologica; 2023 May; 108(5):1374-1384. PubMed ID: 36172814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Mayo Additive Staging System in patients with newly diagnosed multiple myeloma: A real-world analysis.
    Chen H; Shi H; Zhou N; Yu W; Wu L; Peng R; Wei W; Wang D; Zhou F
    Eur J Haematol; 2023 Mar; 110(3):229-235. PubMed ID: 36366975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prognostic value of the revised international staging system for newly diagnosed multiple myeloma patients].
    Lu J; Du J; Fu WJ; He HY; Li L; Li R; Zhou LL; Jiang H; Hou J
    Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):475-479. PubMed ID: 28655089
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.